Comment on Ostrominski et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations
We read with interest the report by Ostrominski et al. (1), which used two target-trial emulations to compare tirzepatide with dulaglutide or semaglutide among patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study is timely and carefully constructed. Our concern is not whether...